食药用大型真菌次生代谢产物的生物活性

Biological Activities of Secondary Metabolites from the Edible-Medicinal Macrofungi.

作者信息

Sun Xiaoqi, Shi Ying, Shi Dongxiao, Tu Yu, Liu Ling

机构信息

State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.

University of Chinese Academy of Sciences, Beijing 100049, China.

出版信息

J Fungi (Basel). 2024 Feb 11;10(2):144. doi: 10.3390/jof10020144.

DOI:10.3390/jof10020144

PMID:38392816

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10890728/

Abstract

Macrofungi are well-known as edible-medicinal mushrooms, which belong mostly to Basidiomycota, with a few from Ascomycota. In recent years, macrofungi have been recognized as a rich resource of structurally unique secondary metabolites, demonstrating a wide range of bioactivities, including anti-tumor, antioxidant, anti-inflammatory, antimicrobial, antimalarial, neuro-protective, hypoglycemic, and hypolipidemic activities. This review highlights over 270 natural products produced by 17 families of macrofungi covering 2017 to 2023, including their structures, bioactivities, and related molecular mechanisms.

摘要

大型真菌以食药用菌而闻名，它们大多属于担子菌门，少数属于子囊菌门。近年来，大型真菌被认为是结构独特的次生代谢产物的丰富来源，具有广泛的生物活性，包括抗肿瘤、抗氧化、抗炎、抗菌、抗疟疾、神经保护、降血糖和降血脂活性。本综述重点介绍了2017年至2023年期间17个大型真菌家族产生的270多种天然产物，包括它们的结构、生物活性和相关分子机制。